Rhodes Jason P

DirectorDyne Therapeutics, Inc. (DYN) · full profile →Form 4 · filed Apr 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$16.5M
Net Open-Market Flow
-$16.5M
Transactions
16
16 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 22, 2026Sell(S)76K$19.68$1.5M1.7M
Apr 22, 2026Sell(S)1K$19.68$29K12K
Apr 22, 2026Sell(S)151K$19.68$3.0M5.3M
Apr 22, 2026Sell(S)60K$19.68$1.2M1.3M
Apr 21, 2026Sell(S)56K$19.51$1.1M1.3M
Apr 21, 2026Sell(S)2K$20.05$31K5.4M
Apr 21, 2026Sell(S)15$20.05$30113K
Apr 21, 2026Sell(S)605$20.05$12K1.3M
Apr 21, 2026Sell(S)769$20.05$15K1.8M
Apr 21, 2026Sell(S)71K$19.51$1.4M1.8M
Apr 21, 2026Sell(S)142K$19.51$2.8M5.4M
Apr 21, 2026Sell(S)1K$19.51$27K13K
Apr 20, 2026Sell(S)72K$20.06$1.4M1.9M
Apr 20, 2026Sell(S)56K$20.06$1.1M1.4M
Apr 20, 2026Sell(S)1K$20.06$28K15K
Apr 20, 2026Sell(S)143K$20.06$2.9M5.6M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001577014-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly: